MIR182_KIDNEY-TX

miR-182 as new Therapeutical Target in Renal Transplantation

 Coordinatore MEDIZINISCHE UNIVERSITAET WIEN 

 Organization address address: SPITALGASSE 23
city: WIEN
postcode: 1090

contact info
Titolo: Prof.
Nome: Rainer
Cognome: Oberbauer
Email: send email
Telefono: +43 664 5066600

 Nazionalità Coordinatore Austria [AT]
 Totale costo 261˙326 €
 EC contributo 261˙326 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2012-IOF
 Funding Scheme MC-IOF
 Anno di inizio 2014
 Periodo (anno-mese-giorno) 2014-02-01   -   2017-01-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    MEDIZINISCHE UNIVERSITAET WIEN

 Organization address address: SPITALGASSE 23
city: WIEN
postcode: 1090

contact info
Titolo: Prof.
Nome: Rainer
Cognome: Oberbauer
Email: send email
Telefono: +43 664 5066600

AT (WIEN) coordinator 261˙326.40

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

transplantation    renal    mechanisms    molecular    allograft    inhibition    first    rat    kidney    week    genes    kidneys    mir    dgf    deceased    donor    mirnas    inflammatory   

 Obiettivo del progetto (Objective)

'Delayed graft function (DGF) after kidney transplantation represents the main risk factor for allograft loss. While DGF occurs rarely after living donor transplantation, about 25% of deceased donor kidney recipients develop DGF and require dialysis within the first week after transplantation. Various molecular mechanisms have been elucidated. Pro-inflammatory response after brain death and ischemic reperfusion injury are significant factors contributing to development of DGF. Nevertheless, prevention of DGF after transplantation is desirable but still not feasible.

MicroRNAs (miRNAs) are a class of small non-coding 18 to 24 nucleotide-long RNAs involved in the regulation of diverse cellular functions and in the pathogenesis of DGF. One of the most appealing properties of miRNAs as therapeutic agents is their ability to target multiple molecules, making them extremely efficient in regulating distinct biological cell processes relevant in specific diseases. One of their members, miR-182 is strongest increased during acute renal transplant failure. miR-182 regulates approx. 50% of significantly deregulated genes in renal allograft biopsies developing DGF within the first week after transplantation. Furthermore the inhibition of miR-182 showed anti-inflammatory properties over the target gene FOXO1.

Aims: 1. We will investigate whether the inhibition of miR-182 will revert transcriptional activation of genes involved in DGF in the rat donor kidney 2. To elucidate the efficacy of miR-182 antisense in preventing the incidence and duration of postischemic DGF in a rat model. 3. The third aim is to test the proposed treatment in human deceased donor kidneys, which are declined for transplantation. Machine perfusion technique (lifeport®) will be used to apply the drug into the donor kidneys ex vivo.

This study translates recent knowledge on the molecular mechanisms of DGF into a potentially applicable prophylactic intervention.'

Altri progetti dello stesso programma (FP7-PEOPLE)

NEURAL DEVELOPMENT (2011)

Development of the circuits in the locust brain for the early detection and avoidance of looming objects

Read More  

NETDYNCORTEX (2010)

Network dynamics of auditory cortex and the impact of correlations on the encoding of sensory information

Read More  

FGLYP (2012)

FLUORINATED SUGARS: CHEMICAL TOOLS FOR THE STUDY OF CARBOHYDRATE-BINDING PROTEINS

Read More